<b>Gapping up</b><br/><b>In reaction to earnings/guidance: </b>VIPS +10.1%, ROX +6.7%, VDSI +6.1%, Z +4.2%, GT +4.2%, TTS +3.4%, QSR +2.7%, WM +2.7%, MDT +2.3%, ITRN +2.1%, GIS +1.1%, FDP +1.1%, HK +1%, USAT +0.5%<br/><br/><b>M&A news: </b>CCG +5.6% (announces exploration of strategic alternatives), LMNS +1.5% (reports of Fosun (FOSUF) interest)<br/><br/><b>Select oil/gas related names showing early strength:</b> GDP +3.9%, SDRL +3.9%, NBL +2.4%, PBR +1.9%, OAS +1.5%, WLL +1.3%, PWE +0.8%, BHI +0.8%<br/><br/><b>Other news: </b>IBIO +40% (following 60 Minutes special this weekend on partner Mapp Pharma's ZMapp product as a treatment for Ebola), ONCY +29.4% (confims that the FDA has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer), GEVO +20.1% (cont strength), GENE +16.9% (cont pre-mkt vol), RXDX +7.1% (confirms it Received Orphan Drug Designation from FDA for Entrectinib for the Treatment of Molecularly Defined Subsets of Colorectal Cancer), CEL +6.5% (announces collective employment agreement), NAVB +5.6% (peer-reviewed publication of results from a Phase 3 clinical trial; results demonstrated that Lymphoseek met the primary efficacy endpoint), PSTI +5.2% (still checking), CYRN +4.6% (announced that ALSO Deutschland GmbH now distributes the cloud-based CYREN WebSecurity solution), CANF +3.6% (receives notice of allowance in U.S. for Psoriasis patent), MHR +3.4% (announces 2015 upstream capital expenditure budget; flexible 2015 upstream budget of $100 mln), RTK +3.2% (announces that GSO Capital Partners has increased its credit facility for Rentech by up to $63 million), CYTX +3% (announces the first patient has been treated in its FDA approved trial assessing the effect of Cytori Cell Therapy for osteoarthritis of the knee), NVAX +2.5% (favorable commentary on Friday's Mad Money), HOT +2.5% (announced that Frits van Paasschen has resigned as CEO), ACT +1.6% (launches generic Pulmicort RESPULES), NICE +1.4% (announces Sarit Sagiv as its new CFO), NEE +1.4% (announces CFO transition plan)<br/><br/><b>Analyst comments: </b>SRPT +7.8% (upgraded to Buy from Neutral at BofA/Merrill), EURN +5.1% (initiated with a Buy at Citigroup), FEYE +1.5% (target raised to $49 from $44 at BofA/Merrill), GPRO +1.2% (initiated with a Outperform at Northland Capital), MU +1.1% (upgraded to Outperform from Neutral at Macquarie), BBVA +1% (upgraded to Outperform from Underperform at Exane BNP Paribas)<br/><br/><b>Gapping down</b><br/><b>In reaction to disappointing earnings/guidance</b>: RGSE -17.9%, HLX -11.4%, WLT -10.1%, IHG -5.6%, VNR -5.1%, AGIO -3.8%, WWW -3.5%, GLF -2.6%, USTR -1.5%, CADC -1.5%, CRY -0.9%, EPE -0.8%, MGM -0.8%, SYKE -0.7%, PES -0.7%<br/><br/><b>Select silver/mining stocks trading lower: </b>SSRI -3.3%, SLV -3.0%, PAAS -2.4%, SLW -2%<br/><br/><b>Other news: </b>CLTX -82.3% (announces Phase II trial of MRX-6 cream 2% in pediatric Atopic Dermatitis did not reach primary endpoint), VBLT -44.7% (announces removal of FDA partial clinical hold on VB-111), WHX -21.7% (NYSE suspends trading, company expects trading to move to OTC effective with the opening of trading on February 17, 2015), JOEZ -12.4% (disclosed it received an additional notice of defaults and events of default), NBG -10.6% (no resolution in Greece/EU talks), MNST -2.5% (disclosed that in relation to its previously announced agreement with Coca-Cola (KO), it expects to incur costs associated with the transition of its distribution arrangements in an amount currently estimated to be $280 mln), QTWO -2.3% (files for offering of ~4.56 mln shares of common stock: co selling 1.5 mln shares, selling stockholders selling ~3.06 mln shares), ASML -2% (still checking), ARMH -1.8% (still checking), GSK -1.6% (still checking), AZN -1.5% (US District Court rules PULMICORT RESPULES patent is invalid), GGP -0.9% (disclosed that it has extended its employment agreement with CEO Sandeep Mathrani for an initial five year term)<br/><br/><b>Analyst comments:</b> BID -4.3% (downgraded to Market Perform from Outperform at Cowen), CVC -1.7% (downgraded to Sell from Neutral at UBS), M -1.4% (initiated with an Underweight at Barclays), LYB -1.2% (downgraded to Neutral from Buy at Citigroup), JWN -1.1% (downgraded to Underweight at Barclays), ZAYO -1.1% (downgraded to Underperform from Neutral at Macquarie)<br/>Allikas: Briefing.com